Clinical Focus

• Infectious Disease

Professional Education

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Clinical Trials

• The Stanford HIV Aging Group (SHAG) Recruiting
• A5281: A Phase I Randomized, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of a Cytokine Enhanced HIV-1 Multi-Antigen (HIV MAG) pDNA Vaccine Delivered Intramuscularly Followed by in Vivo Electroporation (IM/EP) or Intramuscularly in HIHIV-1 Infected Adults Receiving ART Recruiting
• A5286: A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals with Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy Recruiting
• A5303: A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel, Maraviroc-containing Antiretroviral Regimen in Treatment-Na·ve Patients Infected with R5-tropic HIV-1 Recruiting
• ACTG 5275: A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals with Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL Recruiting

Publications

• Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis. Bendavid E, Grant P, Talbot A, Owens DK, Zolopa A. AIDS. 2011; 25 (2): 211-20
• Concerns regarding a randomized study of the timing of antiretroviral therapy in zimbabweans with AIDS and acute cryptococcal meningitis. Grant PM, Aberg JA, Zolopa AR. Clin Infect Dis. 2010; 51 (8): 984-5; author reply 987-9
• International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase. Grant PM, Taylor J, Nevins AB, Calvez V, Marcelin AG, Wirden M, Zolopa AR. Antimicrob Agents Chemother. 2010; 54 (4): 1520-5
• Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance. Grant PM, Zolopa AR. Curr Opin Investig Drugs. 2010; 11 (8): 901-10
• Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors. Talbot A, Grant P, Taylor J, Baril JG, Liu TF, Charest H, Brenner B, Roger M, Shafer R, Cantin R, Zolopa A. Antimicrob Agents Chemother. 2010; 54 (6): 2473-9